» Articles » PMID: 32165870

The Impact of Ultraviolet- and Infrared-based Laser Microdissection Technology on Phosphoprotein Detection in the Laser Microdissection-reverse Phase Protein Array Workflow

Overview
Journal Clin Proteomics
Publisher Biomed Central
Date 2020 Mar 14
PMID 32165870
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Reversible protein phosphorylation represents a key mechanism by which signals are transduced in eukaryotic cells. Dysregulated phosphorylation is also a hallmark of carcinogenesis and represents key drug targets in the precision medicine space. Thus, methods that preserve phosphoprotein integrity in the context of clinical tissue analyses are crucially important in cancer research. Here we investigated the impact of UV laser microdissection (UV LMD) and IR laser capture microdissection (IR LCM) on phosphoprotein abundance of key cancer signaling protein targets assessed by reverse-phase protein microarray (RPPA). Tumor epithelial cells from consecutive thin sections obtained from four high-grade serous ovarian cancers were harvested using either UV LMD or IR LCM methods. Phosphoprotein abundances for ten phosphoproteins that represent important drug targets were assessed by RPPA and revealed no significant differences in phosphoprotein integrity from those obtained using higher-energy UV versus the lower-energy IR laser methods.

Citing Articles

A modified dual preparatory method for improved isolation of nucleic acids from laser microdissected fresh-frozen human cancer tissue specimens.

Kimble D, Litzi T, Snyder G, Olowu V, TaQee S, Conrads K Biol Methods Protoc. 2024; 9(1):bpae066.

PMID: 39421215 PMC: 11486541. DOI: 10.1093/biomethods/bpae066.


A novel method for the isolation of single cells mimicking circulating tumour cells adhered on Smart Bio Surface slides by Laser Capture Microdissection.

Visci G, Tolomeo D, Lonoce A, Arshadi A, Bascetta L, Trotta G PLoS One. 2024; 19(3):e0297739.

PMID: 38457477 PMC: 10923433. DOI: 10.1371/journal.pone.0297739.


Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.

Gallagher R, Wulfkuhle J, Wolf D, Brown-Swigart L, Yau C, OGrady N Cell Rep Med. 2023; 4(12):101312.

PMID: 38086377 PMC: 10772394. DOI: 10.1016/j.xcrm.2023.101312.


AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.

Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F NPJ Precis Oncol. 2023; 7(1):18.

PMID: 36797347 PMC: 9935518. DOI: 10.1038/s41698-023-00360-5.


Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach.

Baldelli E, Mandarano M, Bellezza G, Petricoin 3rd E, Pierobon M Cell Rep Methods. 2022; 2(8):100271.

PMID: 36046628 PMC: 9421534. DOI: 10.1016/j.crmeth.2022.100271.


References
1.
Fiore L, Rodriguez H, Shriver C . Collaboration to Accelerate Proteogenomics Cancer Care: The Department of Veterans Affairs, Department of Defense, and the National Cancer Institute's Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Network. Clin Pharmacol Ther. 2017; 101(5):619-621. DOI: 10.1002/cpt.658. View

2.
Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

3.
Li J, Xing X, Li D, Zhang B, Mutch D, Hagemann I . Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia. 2017; 19(2):100-111. PMC: 5237802. DOI: 10.1016/j.neo.2016.12.009. View

4.
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L . CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2015; 55(11):1688-1699. PMC: 5057350. DOI: 10.1002/mc.22419. View

5.
Herfs M, Yamamoto Y, Laury A, Wang X, Nucci M, McLaughlin-Drubin M . A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A. 2012; 109(26):10516-21. PMC: 3387104. DOI: 10.1073/pnas.1202684109. View